AI-Driven One-Stop Antibody Discovery Platforms
AI Antibody Discovery Platform
AI-Driven Antibody Design-From Concept to Candidate
Design de novo antibodies, predict developability, and validate faster with an integrated AI × wet-lab loop.
"Creative Biolabs halved our optimization timeline, delivering pM-range binders for challenging GPCR targets."
- Senior Scientist, Top 10 Pharma Partner
Start Your Antibody Discovery Project | Talk to Our Experts
Introduction: Revolutionizing Biologics Development
Are you currently facing long drug development cycles, high attrition rates due to poor developability, or difficulty targeting complex epitopes? Our AI Antibody Discovery Platforms help you obtain high-affinity, developable leads and streamline your path to the clinic through our proprietary AbForge® Platform. By integrating generative protein language models with high-precision structural biology, Creative Biolabs transforms the traditional "trial-and-error" approach into a predictable engineering discipline.
Customer Pain Points: Why Traditional Antibody Discovery Falls Short
Despite advancements in phage display and hybridoma technology, traditional workflows still suffer from inherent biological constraints that often lead to project stagnation:
Limited Library Diversity
Physical libraries often sample only a fraction of the potential sequence space, missing rare but potent binders.
Long Discovery Timelines
Iterative wet-lab rounds of immunization and screening can take months without guaranteeing a "hit."
High Developability Failure Rate
Many high-affinity binders identified in early screening fail during CMC due to aggregation, low solubility, or PTM liabilities.
Complex Epitope Targeting
Traditional methods struggle with "hard targets" like GPCRs, ion channels, or specific allosteric pockets.
Creative Biolabs utilizes AI to break these bottlenecks, shifting the discovery paradigm from observation to rational generation.
Expedite Progress with Creative Biolabs – Initiate Your Consultation Now.
AI-Driven Antibody Design and Discovery
De Novo Antibody Generation
Creative Biolabs utilizes state-of-the-art generative models to design entirely new antibody sequences tailored to specific antigen geometries.
Generative Protein Models
Sampling diverse sequence spaces to find optimized frameworks.
Sequence Space Exploration
Expanding beyond natural repertoires to identify novel paratopes.
IP-Safe Design Strategies
Creating differentiated sequences to navigate complex patent landscapes.
AI-Enabled Virtual Screening
Our high-throughput computational engine evaluates millions of candidates in silico before they ever reach the bench.
Binding Prediction
Deep learning architectures that predict affinity with chemical accuracy.
Structural Modeling
Rapid generation of Fv and Fab models using equivariant neural networks.
Epitope Mapping
Precise identification of target-ligand interfaces to ensure functional blocking.
Structure-Guided Optimization
Once a lead is identified, our AI models perform multi-parameter optimization:
Affinity
Refinement of CDR loops to achieve pM-level binding.
Stability
Optimizing core packing and surface electrostatics.
Manufacturability
Eliminating aggregation hotspots and PTM liabilities (deamidation/isomerization).
Explore How We Can Assist You – Initiate a Consultation Request.
AI-Wet Lab Closed-Loop Discovery
Unlike purely computational platforms, the Creative Biolabs system integrates AI-driven design with rigorous experimental validation at every stage. We call this the AbForge® Closed Loop.
Technology Foundation
Our platform is powered by an industry-leading technical stack:
- Generative AI & LLMs: Large protein language models trained on billions of biological sequences.
- Geometric Deep Learning: Architectures that understand the 3D spatial relationships of atoms at the binding interface.
- Molecular Dynamics (MD): All-atom simulations to assess conformational stability and binding kinetics.
- HPC Clusters: High-performance computing infrastructure capable of running massive FEP (Free Energy Perturbation)
What We Can Offer: Our Three-Step Solution
Step 1 — Generate
AI-generated antibody sequences through de novo design and diverse library expansion.
Step 2 — Evaluate
Comprehensive structural modeling, binding affinity prediction, and developability risk screening.
Step 3 — Validate & Optimize
Recombinant expression followed by experimental validation and AI-led iterative refinement.
Workflow: From Target Definition to Validated Lead
The AbForge® workflow is a structured, stage-gated process designed to minimize risk and maximize translational success.
1. Required Starting Materials
To initiate a project, clients typically provide either the Antigen Protein Sequence/Structure or a Specific Antigen Epitope Definition. Access to any existing "Parent Antibody" sequences for optimization is also beneficial.
2. Target & Epitope Definition
We use structural modeling to identify the optimal "patch" for binding, matching it against 12 clinically validated germlines.
3. AI Design & Exploration
Our models generate a massive repertoire (up to 1M unique sequences) optimized for the target epitope.
4. Virtual Screening & Prioritization
Candidates are ranked using a "Balanced Scorecard" that weights affinity, specificity, and developability.
5. Wet-Lab Validation
Top-K candidates are expressed in mammalian systems and characterized via SPR/BLI and cell-based functional assays.
6. Iterative Optimization
Experimental data is fed back into the AI to "evolve" the best candidates for pM-range affinity.
7. Final Deliverables
Clients receive a Comprehensive Data Package (including all sequence data and structural models), Validated Physical Clones (expressed antibodies), and a Detailed Developability Risk Register.
Estimated Timeframe: The typical timeframe ranges from 8 to 16 weeks, depending on the complexity of the target (e.g., soluble ligand vs. multi-span membrane protein) and the depth of optimization required.
Platform Capabilities
AI De novo Antibody Design
Generate novel sequences beyond natural repertoires with target-specific precision.
Structure-Guided Modeling
Epitope-aware docking and high-confidence binding scoring.
Developability Optimization
Proactive prediction of solubility, aggregation, and manufacturability.
Antibody Engineering
Precision humanization and affinity maturation while maintaining paratope integrity.
Advanced Modalities
Expertise in Bispecific (BsAb) assembly engineering and ADC compatibility.
Case Study: Accelerating Antibody Discovery through AI-Driven De novo Design
-
Precision Epitope Targeting
Using advanced structural modeling, we precisely identified the optimal epitope patch for antibody design. Leveraging our proprietary AI platform, we matched this epitope with 12 clinically validated germline types, laying a solid foundation for subsequent antibody generation.
-
AI-Driven Antibody Generation
Our cutting-edge antibody language model and affinity prediction algorithms were deployed to design and evolve a vast repertoire of candidate antibodies. Through iterative modeling, evolutionary screening, and rigorous risk filtering, we ensured that only sequences with high developability potential were retained.
Outcome: A scalable antibody library with three size options (10K, 200K, and 1M), with the largest containing ~915,000 unique antibody sequences. -
Comprehensive Analysis for Informed Decisions
We provided detailed statistical insights on sequence diversity, CDRH3 length distribution (8–16), amino acid composition, and risk assessments. This comprehensive analysis empowered the client to select the optimal library for downstream screening and development.
Outcome
✓ Final Outcome
The client successfully obtained a highly diverse, high-quality antibody library and comprehensive analytics, enabling efficient experimental screening and advancing their therapeutic pipeline with confidence. Our AI-Driven de novo antibody design approach sets a new benchmark for speed, diversity, and reliability in antibody discovery.
SEQUENCE ANALYSIS RESULTS
Validated Data
Fig.1 Amino acid frequency logo of the designed antibody CDR region. The sequence logo illustrates the positional amino acid preferences within the designed antibody CDRs, reflecting sequence diversity and conserved motifs generated by the AI-powered design pipeline.
Explore Our Assistance Solutions – Book a Consultation Today!
Customer Reviews
Discover the Creative Biolabs Advantage – Request Your Quote Now
Trusted by Global R&D Teams
Creative Biolabs is recognized by biopharma innovators worldwide for delivering measurable acceleration, reproducibility, and clarity from AI modeling to experimental validation.
Why Choose Us?
Integrated Solutions
Seamless transition from AI prediction to wet-lab validation under one roof.
Decades of Expertise
20 years of experience in complex antibody engineering and discovery.
Proprietary AI Models
Specialized models for 3D structure prediction.
Global Reach
Serving over 10,000 customers with a 90% repeat-client rate.
Risk Mitigation
Early detection of PTM and aggregation liabilities to ensure clinical success.
Frequently Asked Questions
Q: How does AI-driven de novo design compare to phage display?
A: While phage display relies on the physical constraints of a library, AI de novo design explores a nearly infinite sequence space, allowing for the creation of antibodies against epitopes that are "silent" or difficult to target in biological systems.
Q: What is the success rate for difficult targets like GPCRs?
A: Our success rate is significantly higher due to our Structure-Based Modeling. By identifying allosteric pockets and predicting binding geometries in silico, we focus wet-lab resources only on the most promising candidates.
Q: Can your AI platform reduce the risk of immunogenicity?
A: Yes. We front-load T-cell epitope screening during the design phase, proposing minimally disruptive substitutions that preserve binding function while reducing the risk of clinical ADA (Anti-Drug Antibodies).
Q: Do I retain the IP for antibodies designed by your AI?
A: Absolutely. Creative Biolabs operates as a CRO; all designs, sequences, and physical materials generated for your project are your exclusive intellectual property.
Q: How "wet-lab ready" are the AI-generated sequences?
A: Every sequence undergoes a "Developability Quick Screen." We optimize for solubility, stability, and expression titers during the design phase to ensure a 90%+ success rate in mammalian expression.
Conclusion: Partner with the Leaders in Molecular AI
Creative Biolabs provides the world's most advanced AI Antibody Discovery Platforms, bridging the gap between computational power and biological reality. Whether you are tackling an "undruggable" target or looking to optimize a promising lead, our AbForge® Platform is designed to deliver clinical-ready assets with unprecedented speed and precision.